A detailed history of Credit Suisse Ag transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Credit Suisse Ag holds 63,024 shares of PTGX stock, worth $2.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,024
Previous 62,517 0.81%
Holding current value
$2.87 Million
Previous $1.43 Million 27.22%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$21.79 - $32.15 $11,047 - $16,300
507 Added 0.81%
63,024 $1.82 Million
Q4 2023

Feb 08, 2024

BUY
$14.05 - $23.44 $174,276 - $290,749
12,404 Added 24.75%
62,517 $1.43 Million
Q3 2023

Nov 13, 2023

SELL
$16.68 - $23.66 $212,186 - $300,978
-12,721 Reduced 20.25%
50,113 $835,000
Q2 2023

Aug 11, 2023

BUY
$18.02 - $29.36 $447,490 - $729,096
24,833 Added 65.35%
62,834 $1.74 Million
Q1 2023

May 10, 2023

BUY
$10.78 - $25.38 $72,915 - $171,670
6,764 Added 21.65%
38,001 $874,000
Q4 2022

Feb 13, 2023

SELL
$7.36 - $11.17 $5,851 - $8,880
-795 Reduced 2.48%
31,237 $340,000
Q3 2022

Nov 10, 2022

BUY
$7.86 - $11.71 $1,705 - $2,541
217 Added 0.68%
32,032 $270,000
Q2 2022

Aug 12, 2022

SELL
$7.06 - $25.52 $7,645 - $27,638
-1,083 Reduced 3.29%
31,815 $251,000
Q1 2022

May 16, 2022

BUY
$23.34 - $36.08 $106,197 - $164,164
4,550 Added 16.05%
32,898 $779,000
Q4 2021

Feb 14, 2022

BUY
$17.63 - $37.1 $11,512 - $24,226
653 Added 2.36%
28,348 $969,000
Q3 2021

Nov 12, 2021

BUY
$12.95 - $49.69 $3,108 - $11,925
240 Added 0.87%
27,695 $491,000
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $158,917 - $278,929
6,215 Added 29.26%
27,455 $1.23 Million
Q1 2021

May 14, 2021

SELL
$19.02 - $31.15 $562,668 - $921,510
-29,583 Reduced 58.21%
21,240 $549,000
Q4 2020

Feb 12, 2021

BUY
$18.49 - $25.13 $431,686 - $586,710
23,347 Added 84.97%
50,823 $1.03 Million
Q3 2020

Nov 13, 2020

BUY
$15.19 - $22.4 $417,360 - $615,462
27,476 New
27,476 $537,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.23B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.